Info

Scientists at Epeius Biotechnologies have developed the world's first targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-GÔ, the first tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and superior single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. , where it has achieved FDA orphan drug status , and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. Our international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with significant efficacy and excellent safety profiles. We are a privately held biopharmaceutical company focused on expanding the therapeutic utility and commercialization of our proprietary pathotropic approach to disease treatment through internal development and commercialization of our oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and proprietary stem cell technologies.